255 related articles for article (PubMed ID: 21125345)
1. Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives.
Thol F; Ganser A
Front Med China; 2010 Dec; 4(4):356-62. PubMed ID: 21125345
[TBL] [Abstract][Full Text] [Related]
2. Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia.
Larson RA
Chem Biol Interact; 2010 Mar; 184(1-2):21-5. PubMed ID: 19822134
[TBL] [Abstract][Full Text] [Related]
3. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Falini B; Martelli MP
Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
[TBL] [Abstract][Full Text] [Related]
4. [Acute myeloid leukemia: molecular pathogenesis and new therapeutic strategies].
Goyama S
Rinsho Ketsueki; 2016 Feb; 57(2):118-28. PubMed ID: 26935629
[TBL] [Abstract][Full Text] [Related]
5. [Gene mutations in acute myeloid leukemia].
Yamaguchi H
Rinsho Ketsueki; 2016; 57(12):2535-2542. PubMed ID: 28090023
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
7. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.
Ghanem H; Tank N; Tabbara IA
Am J Hematol; 2012 Jan; 87(1):69-77. PubMed ID: 22072438
[TBL] [Abstract][Full Text] [Related]
9. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.
Selim AG; Moore AS
J Mol Diagn; 2018 Jul; 20(4):389-397. PubMed ID: 29689379
[TBL] [Abstract][Full Text] [Related]
10. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
[TBL] [Abstract][Full Text] [Related]
11. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD; Bullinger L
Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
[TBL] [Abstract][Full Text] [Related]
12. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
Bullinger L; Döhner K; Döhner H
J Clin Oncol; 2017 Mar; 35(9):934-946. PubMed ID: 28297624
[TBL] [Abstract][Full Text] [Related]
13. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
DiNardo C; Lachowiez C
Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
[TBL] [Abstract][Full Text] [Related]
14. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
Grossmann V; Tiacci E; Holmes AB; Kohlmann A; Martelli MP; Kern W; Spanhol-Rosseto A; Klein HU; Dugas M; Schindela S; Trifonov V; Schnittger S; Haferlach C; Bassan R; Wells VA; Spinelli O; Chan J; Rossi R; Baldoni S; De Carolis L; Goetze K; Serve H; Peceny R; Kreuzer KA; Oruzio D; Specchia G; Di Raimondo F; Fabbiano F; Sborgia M; Liso A; Farinelli L; Rambaldi A; Pasqualucci L; Rabadan R; Haferlach T; Falini B
Blood; 2011 Dec; 118(23):6153-63. PubMed ID: 22012066
[TBL] [Abstract][Full Text] [Related]
15. [Molecular Genetic Testing for Acute Myeloid Leukemia].
Janečková V; Semerád L; Ježíšková I; Dvořáková D; Čulen M; Šustková Z; Mayer J; Ráčil Z
Klin Onkol; 2016; 29(6):411-418. PubMed ID: 27951719
[TBL] [Abstract][Full Text] [Related]
16. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
17. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
19. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
20. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
